Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ.

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.

2.

Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.

Maslah N, Verger E, Schlageter MH, Miclea JM, Kiladjian JJ, Giraudier S, Chomienne C, Cassinat B.

Ann Hematol. 2019 Jan;98(1):111-118. doi: 10.1007/s00277-018-3499-y. Epub 2018 Sep 26.

PMID:
30259120
3.

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.

Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ.

Thromb Haemost. 2018 Sep;118(9):1586-1599. doi: 10.1055/s-0038-1667015. Epub 2018 Aug 13.

PMID:
30103245
4.

Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis.

Alex AA, Ganesan S, Palani HK, Balasundaram N, David S, Lakshmi KM, Kulkarni UP, Nisham PN, Korula A, Devasia AJ, Janet NB, Abraham A, Srivastava A, George B, Padua RA, Chomienne C, Balasubramanian P, Mathews V.

Front Immunol. 2018 Jun 14;9:1357. doi: 10.3389/fimmu.2018.01357. eCollection 2018.

5.

Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.

Lucchesi C, Khalifa E, Laizet Y, Soubeyran I, Mathoulin-Pelissier S, Chomienne C, Italiano A.

JAMA Oncol. 2018 Oct 1;4(10):1398-1404. doi: 10.1001/jamaoncol.2018.0723.

PMID:
29801054
6.

New chimeric RNAs in acute myeloid leukemia.

Rufflé F, Audoux J, Boureux A, Beaumeunier S, Gaillard JB, Bou Samra E, Megarbane A, Cassinat B, Chomienne C, Alves R, Riquier S, Gilbert N, Lemaitre JM, Bacq-Daian D, Bougé AL, Philippe N, Commes T.

Version 2. F1000Res. 2017 Aug 2 [revised 2017 Jan 1];6. pii: ISCB Comm J-1302. doi: 10.12688/f1000research.11352.2. eCollection 2017.

7.

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

Brusson M, De Grandis M, Cochet S, Bigot S, Marin M, Leduc M, Guillonneau F, Mayeux P, Peyrard T, Chomienne C, Le Van Kim C, Cassinat B, Kiladjian JJ, El Nemer W.

Haematologica. 2018 Jun;103(6):972-981. doi: 10.3324/haematol.2017.182303. Epub 2018 Mar 29.

8.

[Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes].

Goulard M, Dosquet C, Chomienne C.

Med Sci (Paris). 2018 Jan;34(1):9-11. doi: 10.1051/medsci/20183401002. Epub 2018 Jan 31. French. No abstract available.

9.

Acute promyelocytic leukemia: a model ofpersonalized medicine.

Chomienne C.

Rinsho Ketsueki. 2017;58(10):1918-1919. doi: 10.11406/rinketsu.58.1918. No abstract available.

PMID:
28978833
10.

Preclinical modeling of myelodysplastic syndromes.

Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

11.

Correction for Cassinat et al., "New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation".

Cassinat B, Zassadowski F, Ferry C, Llopis L, Bruck N, Lainey E, Duong V, Cras A, Despouy G, Chourbagi O, Beinse G, Fenaux P, Rochette Egly C, Chomienne C.

Mol Cell Biol. 2017 Jun 29;37(14). pii: e00222-17. doi: 10.1128/MCB.00222-17. Print 2017 Jul 15. No abstract available.

12.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T.

Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.

13.

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

Brusson M, Cochet S, Leduc M, Guillonneau F, Mayeux P, Peyrard T, Chomienne C, Le Van Kim C, Cassinat B, Kiladjian JJ, El Nemer W.

Haematologica. 2017 Jul;102(7):e241-e244. doi: 10.3324/haematol.2016.161604. Epub 2017 Apr 6. No abstract available.

14.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ.

J Nucl Med. 2017 Oct;58(10):1603-1608. doi: 10.2967/jnumed.116.188508. Epub 2017 Mar 30.

15.

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Ganesan S, Alex AA, Chendamarai E, Balasundaram N, Palani HK, David S, Kulkarni U, Aiyaz M, Mugasimangalam R, Korula A, Abraham A, Srivastava A, Padua RA, Chomienne C, George B, Balasubramanian P, Mathews V.

Leukemia. 2016 Nov;30(11):2169-2178. doi: 10.1038/leu.2016.227. Epub 2016 Aug 18.

16.

Costs of haematological disease high and rising.

Green T, Bron D, Chomienne C, de Wit TD, de Haas F, Engert A, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler MU, Smand C, Sonneveld P.

Lancet Haematol. 2016 Aug;3(8):e353-4. doi: 10.1016/S2352-3026(16)30074-6. Epub 2016 Jul 22. No abstract available.

PMID:
27476782
17.

Blood disorders stepping into the limelight.

Jäger U, Chomienne C, Cools J, Smand C.

Haematologica. 2016 Feb;101(2):101-3. doi: 10.3324/haematol.2016.142018. Epub 2016 Jan 27. No abstract available.

18.

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera ME, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P.

J Hematol Oncol. 2016 Jan 27;9:5. doi: 10.1186/s13045-016-0235-8.

19.

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.

Patel S, Guerenne L, Gorombei P, Omidvar N, Schlageter MH, Alex AA, Ganesan S, West R, Adès L, Mathews V, Krief P, Pla M, Fenaux P, Chomienne C, Padua RA.

Blood Cancer J. 2015 Dec 11;5:e374. doi: 10.1038/bcj.2015.102. No abstract available.

20.

Unexplained thrombocytosis: association of Baltimore polymorphism with germline MPL nonsense mutation.

Verger E, Teillet F, Conejero C, Letort G, Chomienne C, Giraudier S, Cassinat B.

Br J Haematol. 2016 Oct;175(1):167-9. doi: 10.1111/bjh.13840. Epub 2015 Nov 16. No abstract available.

PMID:
26568271
21.

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ.

Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.

22.

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, Lainey E, Nouri K, Nakhaei-Rad S, Dvorsky R, Lachenaud J, Pereira S, Vivent J, Verger E, Vidaud D, Galambrun C, Picard C, Petit A, Contet A, Poirée M, Sirvent N, Méchinaud F, Adjaoud D, Paillard C, Nelken B, Reguerre Y, Bertrand Y, Häussinger D, Dalle JH, Ahmadian MR, Baruchel A, Chomienne C, Cavé H.

Nat Genet. 2015 Nov;47(11):1334-40. doi: 10.1038/ng.3420. Epub 2015 Oct 12.

PMID:
26457648
23.

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases.

McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F.

Epigenetics Chromatin. 2015 Sep 24;8:38. doi: 10.1186/s13072-015-0030-8. eCollection 2015.

24.

DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.

Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Omidvar N, Tekin N, Bernasconi E, Sicre F, Schlageter MH, Chopin M, Noguera ME, West R, Abu A, Mathews V, Pla M, Fenaux P, Chomienne C, Padua RA.

Oncotarget. 2015 Oct 20;6(32):32494-508. doi: 10.18632/oncotarget.5572.

25.

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.

Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, Beressi JP, Verhoeyen E, Raggueneau V, Maneglier B, Castaigne S, Chomienne C, Chrétien S, Rousselot P, Leboulch P.

Nature. 2015 Sep 17;525(7569):380-3. doi: 10.1038/nature15248. Epub 2015 Sep 2.

PMID:
26331539
26.

AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages.

Six E, Lagresle-Peyrou C, Susini S, De Chappedelaine C, Sigrist N, Sadek H, Chouteau M, Cagnard N, Fontenay M, Hermine O, Chomienne C, Reynier P, Fischer A, André-Schmutz I, Gueguen N, Cavazzana M.

Cell Death Dis. 2015 Aug 13;6:e1856. doi: 10.1038/cddis.2015.211.

27.

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

Zassadowski F, Pokorna K, Ferre N, Guidez F, Llopis L, Chourbagi O, Chopin M, Poupon J, Fenaux P, Ann Padua R, Pla M, Chomienne C, Cassinat B.

Leukemia. 2015 Dec;29(12):2277-84. doi: 10.1038/leu.2015.159. Epub 2015 Jun 25.

PMID:
26108692
28.

An acetyltransferase assay for CREB-binding protein based on reverse phase-ultra-fast liquid chromatography of fluorescent histone H3 peptides.

Duval R, Fritsch L, Bui LC, Berthelet J, Guidez F, Mathieu C, Dupret JM, Chomienne C, Ait-Si-Ali S, Rodrigues-Lima F.

Anal Biochem. 2015 Oct 1;486:35-7. doi: 10.1016/j.ab.2015.06.024. Epub 2015 Jun 20.

PMID:
26099937
29.

Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins.

Chanet R, Kienda G, Heneman-Masurel A, Vernis L, Cassinat B, Guardiola P, Fenaux P, Chomienne C, Huang ME.

PLoS One. 2015 Jun 8;10(6):e0129222. doi: 10.1371/journal.pone.0129222. eCollection 2015.

30.

A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).

Duval R, Bui LC, Berthelet J, Dairou J, Mathieu C, Guidez F, Dupret JM, Cools J, Chomienne C, Rodrigues-Lima F.

Sci Rep. 2015 Jun 4;5:10750. doi: 10.1038/srep10750.

31.

Potentiation of the store-operated calcium entry (SOCE) induces phytohemagglutinin-activated Jurkat T cell apoptosis.

Djillani A, Doignon I, Luyten T, Lamkhioued B, Gangloff SC, Parys JB, Nüße O, Chomienne C, Dellis O.

Cell Calcium. 2015 Aug;58(2):171-85. doi: 10.1016/j.ceca.2015.04.005. Epub 2015 Apr 24.

PMID:
25963393
32.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

33.

Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.

Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM, Viswabandya A, Abraham A, Aiyaz M, Mullapudi N, Mugasimangalam R, Padua RA, Chomienne C, Chandy M, Srivastava A, George B, Balasubramanian P, Mathews V.

PLoS One. 2015 Mar 30;10(3):e0121912. doi: 10.1371/journal.pone.0121912. eCollection 2015.

34.

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

De Grandis M, Cassinat B, Kiladjian JJ, Chomienne C, El Nemer W.

Am J Hematol. 2015 Jul;90(7):E137-8. doi: 10.1002/ajh.24023. Epub 2015 May 28. No abstract available.

35.

Evaluation of a new thyroglobulin sensitive assay in patients with differentiated thyroid cancer.

Schlageter MH, Toubert ME, Meas T, Bouhassira E, Faugeron I, Vimont V, Thomas E, Theimer C, Chomienne C.

Clin Chem Lab Med. 2015 Feb;53(2):e41-3. doi: 10.1515/cclm-2014-0662. No abstract available.

PMID:
25153604
36.

Juvenile myelomonocytic leukaemia and Noonan syndrome.

Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, Pouvreau N, Pereira S, Baumann C, Contet A, Sirvent N, Méchinaud F, Guellec I, Adjaoud D, Paillard C, Alberti C, Zenker M, Chomienne C, Bertrand Y, Baruchel A, Verloes A, Cavé H.

J Med Genet. 2014 Oct;51(10):689-97. doi: 10.1136/jmedgenet-2014-102611. Epub 2014 Aug 5.

PMID:
25097206
37.

TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis.

Verger E, Andreoli A, Chomienne C, Kiladjian JJ, Cassinat B.

Br J Haematol. 2014 May;165(3):416-9. doi: 10.1111/bjh.12738. Epub 2014 Jan 16. No abstract available.

PMID:
24433485
38.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
39.

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA.

Blood. 2013 Oct 17;122(16):2864-76. doi: 10.1182/blood-2012-07-445635. Epub 2013 Aug 13.

40.

A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Lecourt S, Mouly E, Freida D, Cras A, Ceccaldi R, Heraoui D, Chomienne C, Marolleau JP, Arnulf B, Porcher R, Caillaud C, Vanneaux V, Belmatoug N, Larghero J.

PLoS One. 2013 Jul 25;8(7):e69293. doi: 10.1371/journal.pone.0069293. Print 2013.

41.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

42.

In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.

Strullu M, Caye A, Cassinat B, Fenneteau O, Touzot F, Blauwblomme T, Rodriguez R, Latour S, Petit A, Barlogis V, Galambrun C, Leblanc T, Baruchel A, Chomienne C, Cavé H.

Leukemia. 2013 Dec;27(12):2404-7. doi: 10.1038/leu.2013.203. Epub 2013 Jul 4. No abstract available.

PMID:
23823657
43.

Age and aging in blood disorders: EHA theme of the year 2013-2014.

Chomienne C, McCann S, Green T, Hagenbeek A, Lacombe C, Guenova M, Roberts I, van der Beek I.

Haematologica. 2013 Jun;98(6):831-2. doi: 10.3324/haematol.2013.090415. No abstract available.

44.

The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.

Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F.

EMBO J. 2013 Jul 3;32(13):1941-52. doi: 10.1038/emboj.2013.118. Epub 2013 May 31.

45.

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.

Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P; European APL group.

Am J Hematol. 2013 Jul;88(7):556-9. doi: 10.1002/ajh.23451. Epub 2013 Jun 12.

46.

Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.

Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C.

Cancer Res. 2013 Feb 1;73(3):1037-45. doi: 10.1158/0008-5472.CAN-12-3678. Epub 2013 Jan 23. Review.

47.

Quality of life in hematology: European Hematology Association theme of the year...and years to come.

Chomienne C, Guenova M, Hagenbeek A, Lacombe C, McCann S, Salek S, Geissler J, van der Beek I.

Haematologica. 2013 Jan;98(1):2-3. doi: 10.3324/haematol.2012.080796. No abstract available.

48.

JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.

De Grandis M, Cambot M, Wautier MP, Cassinat B, Chomienne C, Colin Y, Wautier JL, Le Van Kim C, El Nemer W.

Blood. 2013 Jan 24;121(4):658-65. doi: 10.1182/blood-2012-07-440487. Epub 2012 Nov 16.

49.

Modulation of endoplasmic reticulum calcium pump expression during lung cancer cell differentiation.

Arbabian A, Brouland JP, Apáti Á, Pászty K, Hegedűs L, Enyedi Á, Chomienne C, Papp B.

FEBS J. 2013 Nov;280(21):5408-18. doi: 10.1111/febs.12064. Epub 2012 Dec 11.

50.

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.

Le Pogam C, Krief P, Beurlet S, Soulié A, Balitrand N, Cassinat B, Cavé H, Kosmider O, Setterblad N, Leboeuf C, Sarda-Mantel L, Hervatin F, Merlet P, Noguera ME, Janin A, Pla M, Fontenay M, Adès L, Fenaux P, Chomienne C, Padua RA, Omidvar N.

Leuk Res. 2013 Mar;37(3):312-9. doi: 10.1016/j.leukres.2012.10.018. Epub 2012 Nov 12.

PMID:
23153525

Supplemental Content

Loading ...
Support Center